A peanut-allergy patch just failed a key study - and the drugmaker's stock is getting crushed
Courtesy of DBV Technologies
- DBV Technologies has been testing a patch meant to ease allergic reactions to peanuts.
- The company said it didn't hit its main goal of achieving more tolerance with the patch than the placebo.
- DBV plans to submit its findings to the FDA anyway.
A potential treatment for one of the most common food allergies out there just failed a key trial.
Roughly 1.5 million children in the US are allergic to peanuts, an allergy that can often be so severe that even the smallest amount of contact can set off an extreme reaction.
To counter that, DBV Technologies has been testing a patch designed to lessen that severity of the allergic reaction.
But in a late-stage trial, DBV wasn't able to hit a key statistic measurement needed to consider the trial a success.
DBV said of the patients who took part in the trial, 35% of those who took the patch responded after a year, while 13.6% of those who took the placebo patch responded. Responding to the treatment either meant that they could be exposed to a certain amount more peanut protein than when they started the trial.
DBV said it still plans to proceed toward submitting the data to the FDA for approval. DBV's stock was down as much as 60% on Friday following the news.
"We believe that this preliminary analysis shows significant therapeutic promise in the peanut-allergic population, where there is a high unmet medical need and no approved treatments," DBV CEO Dr. Pierre-Henri Benhamou said in a statement. Markets Insider
How the patch works
The immune-system-targeting drug is delivered through the skin through a process called epicutaneous immunotherapy.
Inside each patch is a sprayed-on sample of peanut protein. Once you put it on, the protein makes its way into your immune system through your skin. Since it's delivered this way, the allergen never makes it to the bloodstream, which would cause the allergic reaction you're trying to avoid.
The patch treatment is a departure from the way allergies are typically treated. Typically, the only way to lessen an allergic reaction is through "desensitization," a process in which you gradually introduce small amounts of the allergen into your body. In the case of peanut allergies, that means eating the peanut protein outright.
That method can be risky, as it can cause an allergic reaction that spreads throughout the body through the bloodstream. Other, more common methods, for treating allergies have been focused on treating the symptoms of the allergic reaction - i.e., using antihistamines like Benadryl or shots of epinephrine in extreme cases.
- I spent $2,000 for 7 nights in a 179-square-foot room on one of the world's largest cruise ships. Take a look inside my cabin.
- Saudi Arabia wants China to help fund its struggling $500 billion Neom megaproject. Investors may not be too excited.
- Colon cancer rates are rising in young people. If you have two symptoms you should get a colonoscopy, a GI oncologist says.
- Catan adds climate change to the latest edition of the world-famous board game
- Tired of blatant misinformation in the media? This video game can help you and your family fight fake news!
- Tired of blatant misinformation in the media? This video game can help you and your family fight fake news!
- JNK India IPO allotment – How to check allotment, GMP, listing date and more
- Indian Army unveils selfie point at Hombotingla Pass ahead of 25th anniversary of Kargil Vijay Diwas
- JNK India IPO allotment date
- JioCinema New Plans
- Realme Narzo 70 Launched
- Apple Let Loose event
- Elon Musk Apology
- RIL cash flows
- Charlie Munger
- Feedbank IPO allotment
- Tata IPO allotment
- Most generous retirement plans
- Broadcom lays off
- Cibil Score vs Cibil Report
- Birla and Bajaj in top Richest
- Nestle Sept 2023 report
- India Equity Market